Operable non-small cell lung cancer: induction therapy, adjuvant therapy, or both?
作者信息
Agrafiotis Apostolos C, Van Schil Paul E
机构信息
Department of Thoracic and Vascular Surgery, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium.
出版信息
J Thorac Dis. 2023 Jul 31;15(7):3519-3521. doi: 10.21037/jtd-23-678. Epub 2023 Jun 26.
Abstract
摘要
相似文献
1
Operable non-small cell lung cancer: induction therapy, adjuvant therapy, or both?可手术的非小细胞肺癌：诱导治疗、辅助治疗，还是两者皆用？
J Thorac Dis. 2023 Jul 31;15(7):3519-3521. doi: 10.21037/jtd-23-678. Epub 2023 Jun 26.
2
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.肺癌的新辅助和辅助表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗。
Transl Lung Cancer Res. 2015 Feb;4(1):82-93. doi: 10.3978/j.issn.2218-6751.2014.11.08.
3
Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study.新辅助免疫检查点抑制剂联合化疗、EGFR-TKI与单纯化疗的非小细胞肺癌患者围手术期结局比较：一项真实世界证据研究
Transl Lung Cancer Res. 2022 Jul;11(7):1468-1478. doi: 10.21037/tlcr-22-476.
4
Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.免疫检查点抑制剂治疗携带表皮生长因子受体突变的非小细胞肺癌患者的临床结局。
BMC Pulm Med. 2023 May 5;23(1):158. doi: 10.1186/s12890-023-02466-9.
5
Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.免疫检查点抑制剂治疗在 EGFR 突变阳性 NSCLC 伴脑转移患者中对 EGFR-TKI 治疗失败的疗效。
Front Immunol. 2022 Sep 27;13:955944. doi: 10.3389/fimmu.2022.955944. eCollection 2022.
6
Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis.EGFR 酪氨酸激酶抑制剂在可手术非小细胞肺癌辅助治疗中的疗效：一项荟萃分析。
Chest. 2016 Jun;149(6):1384-92. doi: 10.1016/j.chest.2015.12.017. Epub 2015 Dec 24.
7
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.表皮生长因子受体酪氨酸激酶抑制剂治疗前后表皮生长因子受体突变的非小细胞肺癌中的肿瘤免疫微环境：一篇叙述性综述
Transl Lung Cancer Res. 2021 Sep;10(9):3823-3839. doi: 10.21037/tlcr-21-572.
8
Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials.表皮生长因子受体酪氨酸激酶抑制剂在表皮生长因子受体突变型非小细胞肺癌切除术后辅助治疗中的疗效：一项包含 11 项试验的荟萃分析。
Oncol Res Treat. 2021;44(6):344-353. doi: 10.1159/000515230. Epub 2021 May 5.
9
Pulmonary complications of tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with non-small cell lung cancer.非小细胞肺癌患者酪氨酸激酶抑制剂和免疫检查点抑制剂的肺部并发症。
Cancer Treat Res Commun. 2021;28:100439. doi: 10.1016/j.ctarc.2021.100439. Epub 2021 Jul 23.
10
Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.PD-L1 表达水平≥50%的晚期 NSCLC 患者在出现 EGFR-TKI 耐药后接受 ICI 治疗的疗效。
Front Immunol. 2023 May 17;14:1161718. doi: 10.3389/fimmu.2023.1161718. eCollection 2023.
本文引用的文献
1
The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review.可切除非小细胞肺癌诱导治疗新时代的开端：一项叙述性综述
J Thorac Dis. 2023 Feb 28;15(2):747-758. doi: 10.21037/jtd-22-957. Epub 2023 Feb 2.
2
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.辅助奥希替尼治疗 EGFR 突变型 IB-IIIA 期非小细胞肺癌：III 期随机 ADAURA 试验的更新结果。
J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.1200/JCO.22.02186. Epub 2023 Jan 31.
3
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).新辅助纳武利尤单抗联合化疗治疗可手术 IIIA 期非小细胞肺癌的总生存和生物标志物分析（NADIM Ⅱ期试验）。
J Clin Oncol. 2022 Sep 1;40(25):2924-2933. doi: 10.1200/JCO.21.02660. Epub 2022 May 16.
4
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
5
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for -mutated resectable non-small-cell lung cancer: NeoADAURA.奥希替尼新辅助治疗联合/不联合化疗对比单纯化疗用于可切除 - 突变型非小细胞肺癌：NeoADAURA 研究。
Future Oncol. 2021 Nov;17(31):4045-4055. doi: 10.2217/fon-2021-0549. Epub 2021 Jul 19.
Zotero 插件